Davis Polk advised European Biotech Acquisition Corp. on the deal while Cooley and Vischer represented Oculis. European Biotech Acquisition Corp. (EBAC), a SPAC, signed its $200 million...
European Biotech Acquisition’s $200 Million Combination With Oculis
Oculis SA’s $57 Million Series C Financing Round
Vischer advised Oculis SA on the deal, while Walder Wyss advised Hyfinity Investments. Oculis S.A., a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to...